Literature DB >> 32620183

Clostridiodes difficile in COVID-19 Patients, Detroit, Michigan, USA, March-April 2020.

Saraswathi Lakkasani, Kok Hoe Chan, Hamid S Shaaban.   

Abstract

Entities:  

Keywords:  2019 novel coronavirus disease; COVID-19; Clostridiodes difficile; IFN-γ; IL-12; SARS-CoV-2; bacteria; coronavirus; coronavirus disease; enteric infections; gastrointestinal symptoms; innate immunity; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses

Mesh:

Year:  2020        PMID: 32620183      PMCID: PMC7454088          DOI: 10.3201/eid2609.202505

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Sandhu et al. () reported 9 patients who were co-infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Clostridioides difficile. C. difficile infection (CDI) can be a co-occurrence or result of antimicrobial drug overuse and is potentially a complication of coronavirus disease (COVID-19). We report a 52-year-old man with hypertension who had fever, respiratory symptoms, abdominal pain, and diarrhea for 3 days. At admission to Saint Michael’s Medical Center (Newark, New Jersey, USA), he had a temperature of 101.8°F but was otherwise hemodynamically stable. He had an elevated absolute lymphocyte count (700 cells/μL), indicating lymphopenia. He tested positive for SARS-CoV-2 RNA by reverse transcription PCR and had elevated inflammatory markers on blood profile. He tested positive for C. difficile toxin and antigen at admission. He did not use antimicrobial drugs or proton pump inhibitors and had no known contacts with persons with diarrhea. He was mechanically ventilated and received oral vancomycin, intravenous metronidazole, and vasopressors. He died of respiratory failure and septic shock. In comparison to the patients described by Sandhu et al., the patient we report was younger and did not have a history of antimicrobial use. SARS-CoV-2 has multifaceted presentations. Angiotensin-converting enzyme 2 receptor, which can act as a receptor for severe acute respiratory syndrome coronavirus, is expressed not only in alveolar cells but also in the gastrointestinal tract, including colonic cells (,). Diarrhea associated with COVID-19 might erode the normal microbial flora of the gut, leading to increased risk for CDI. Also, COVID-19 might weaken the immune system, leaving the patient vulnerable to CDI. COVID-19 patients produce inadequate interferon-γ and have defective macrophage activation and function, resulting in a dysregulated immune response (). Interleukin-12 and interferon-γ are components of cell-mediated immunity. Interferon-γ produced by T-helper cells induces macrophages to destroy bacteria such as C. difficile (). The relationship between SARS-CoV-2 and CDI is still poorly understood. CDI might be a complication of COVID-19; however, we could not exclude the possibility of co-occurrence of CDI with COVID-19. Physicians should consider CDI when encountering a COVID-19 patient with diarrhea.
  5 in total

Review 1.  Close Encounters of Lymphoid Cells and Bacteria.

Authors:  Aranzazu Cruz-Adalia; Esteban Veiga
Journal:  Front Immunol       Date:  2016-10-07       Impact factor: 7.561

2.  Clostridioides difficile in COVID-19 Patients, Detroit, Michigan, USA, March-April 2020.

Authors:  Avnish Sandhu; Glenn Tillotson; Jordan Polistico; Hossein Salimnia; Mara Cranis; Judy Moshos; Lori Cullen; Lavina Jabbo; Lawrence Diebel; Teena Chopra
Journal:  Emerg Infect Dis       Date:  2020-05-22       Impact factor: 6.883

3.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis.

Authors:  I Hamming; W Timens; M L C Bulthuis; A T Lely; G J Navis; H van Goor
Journal:  J Pathol       Date:  2004-06       Impact factor: 7.996

4.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.

Authors:  Daniel Blanco-Melo; Benjamin E Nilsson-Payant; Wen-Chun Liu; Skyler Uhl; Daisy Hoagland; Rasmus Møller; Tristan X Jordan; Kohei Oishi; Maryline Panis; David Sachs; Taia T Wang; Robert E Schwartz; Jean K Lim; Randy A Albrecht; Benjamin R tenOever
Journal:  Cell       Date:  2020-05-15       Impact factor: 41.582

5.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.

Authors:  Wenhui Li; Michael J Moore; Natalya Vasilieva; Jianhua Sui; Swee Kee Wong; Michael A Berne; Mohan Somasundaran; John L Sullivan; Katherine Luzuriaga; Thomas C Greenough; Hyeryun Choe; Michael Farzan
Journal:  Nature       Date:  2003-11-27       Impact factor: 49.962

  5 in total
  2 in total

1.  Outcomes in Patients with SARS-CoV-2 and Clostridioides difficile Coinfection.

Authors:  Kanika Sehgal; Hind J Fadel; Aaron J Tande; Darrell S Pardi; Sahil Khanna
Journal:  Infect Drug Resist       Date:  2021-04-28       Impact factor: 4.003

Review 2.  Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls.

Authors:  Avnish Sandhu; Teena Chopra
Journal:  Therap Adv Gastroenterol       Date:  2021-12-23       Impact factor: 4.409

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.